The Epstein Files Are an IQ Test
Anti-Israel Groups Are Targeting Jewish Children's Camps Now
'Sinners' Actress Says She Can't Enjoy Her Oscar Nomination. Guess Why.
Chicago Reporter Violently Attacked by Career Criminal
Legendary Actor and Director Robert Duvall Dead at 95
The Left Is Lying (Again) About Miscarriages and Abortion Laws
Chicago Area Teacher Forced to Resign for Supporting ICE Speaks Out
Hillary Clinton Lied About Deportations Under Her Husband and Obama
Rolling Stone Wonders Why Apple Hasn't Streamed This Widely-Mocked Show Yet
My Days of Not Taking CNN Seriously Are Coming to a Middle
Armed Protesters Take Issue With Trump's Post-Alex Pretti Comments
CNN Confronts Chuck Schumer on Voter ID
Republican Gubernatorial Candidates Blast Newsom's Presidential Tour in Munich
A Man Joked About Moving Into Billie Eilish's Mansion. Her Response Is Breaking...
These Far-Left Journos Tried Pressuring Jeffries Into Supporting Abolishing ICE. It Didn't...
Tipsheet

Rep. Maloney: Republicans Would Reject Cancer Cure

Rep. Maloney: Republicans Would Reject Cancer Cure

On top of being terrorists and hostage takers, Democrat Rep. Carolyn Maloney apparently thinks Republicans hate cancer patients  because they wouldn't budge on tax hikes during the debt debate.

Advertisement

"If President Obama came in with a cure for cancer they would have turned that down, too," she said.

FLASHBACK: Rationing for cancer patients begins through ObamaCare.

A decision to rescind endorsement of the drug would reignite the highly charged debate over US health care reform and how much the state should spend on new and expensive treatments.

Avastin, the world’s best selling cancer drug, is primarily used to treat colon cancer and was approved by the US Food and Drug Administration in 2008 for use on women with breast cancer that has spread.

It costs $8,000 (£5,000) a month and is given to about 17,500 women in the US a year. The drug was initially approved after a study found that, by preventing blood flow to tumours, it extended the amount of time until the disease worsened by more than five months. However, two new studies have shown that the drug may not even extend life by an extra month.

The FDA advisory panel has now voted 12-1 to drop the endorsement for breast cancer treatment. The panel unusually cited "effectiveness" grounds for the decision. But it has been claimed that "cost effectiveness" was the real reason ahead of reforms in which the government will extend health insurance to the poorest.

 

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement